Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CASP6 | P55212 | 2/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.58 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27326488 | 0.98 | ALDH1A1 (0.61) | ALDH1A1POLBKMT2ACASP6CTDSP1 | |
| SCHEMBL761217 | 0.81 | ALDH1A1 (0.63) | ALDH1A1POLBKMT2ACASP6CTDSP1 | |
| SCHEMBL4111126 | 0.81 | ALDH1A1 (0.63) | ALDH1A1POLBKMT2ACASP6CTDSP1 | |
| SCHEMBL12774648 | 0.81 | ALDH1A1 (0.68) | ALDH1A1POLBKMT2ACASP6CTDSP1 | |
| SCHEMBL15882764 | 0.81 | ALDH1A1 (0.71) | ALDH1A1POLBKMT2ACASP6CTDSP1 | |
| SCHEMBL3903086 | 0.72 | MAPT (0.51) | ALDH1A1POLBKMT2AMEN1LMNA | |
| SCHEMBL1338456 | 0.72 | L3MBTL1 (0.61) | ALDH1A1POLBKMT2ACASP6CTDSP1 | |
| SCHEMBL28338713 | 0.72 | ALDH1A1 (0.55) | ALDH1A1POLBKMT2ACYP1A2CYP2C9 | |
| SCHEMBL1381546 | 0.72 | KDM4E (0.46) | ALDH1A1POLBKMT2AMEN1CYP1A2 | |
| SCHEMBL23016797 | 0.71 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263609-B2 | Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-11 | — | — | US | claimed |
| EP-2007729-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2012-06-27 | — | — | EP | claimed |
| EP-1899296-B1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2010-11-17 | — | — | EP | claimed |
| US-7812040-B2 | such as 3-(3-Acetyl-phenyl)-1-[3-(3-chloro-4-pyrrolidin-1-ylmethyl-phenoxy)-cyclobutylmethyl]-1-methyl-urea, used for the treatment of , schizophrenia, Alzheimer's disease, attention-deficit hyperactivity disorder, hypotension, allergies, cardiovascular, gastrointestinal and psychological disorders | PFIZER INC. (US) | 2010-10-12 | — | — | US | claimed |
| EP-2149573-A1 | Substituted indole sulfonamide compounds their preparation and use as medicaments | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-02-03 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-08-20 | — | — | US | claimed |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-1919475-B1 | TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS | ESTEVE LABOR DR (ES) | 2009-03-11 | — | — | EP | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| EP-1594505-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-16 | — | — | EP | claimed |
| WO-2005077897-A1 | SUBSTITUTED AZETIDINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | claimed |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | LABORATORIOS DE DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | US | claimed |
| EP-1385841-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | claimed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | claimed |
| US-20040142948-A1 | Sulfonamides | DHANAK DASHYANT (US) | 2004-07-22 | — | — | US | claimed |
| EP-1385841-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002090353-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | ALDH1A1 277/4885POLB 4315/4885KMT2A 2608/4885 |
| US-20090131433-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | HRH3, HRH4, HRH2 | ALDH1A1 923/4885POLB 1820/4885KMT2A 1261/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | ALDH1A1 1409/4885POLB 4040/4885KMT2A 592/4885 |
| US-20040204412-A1 | Phenylglycine derivatives useful as serine protease inhibitors | F7, SERPINE1, HABP2 | ALDH1A1 3767/4885POLB 3339/4885KMT2A 1933/4885 |
| US-20090209528-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND, THEIR PREPARATION AND USE IN MEDICAMENTS | HTR6, HTR5A, HTR7 | ALDH1A1 1731/4885POLB 3424/4885KMT2A 2232/4885 |
| US-20050187208-A1 | Substituted Azetidine compounds, their preparation and use as medicaments | AZI2, NISCH, QDPR | ALDH1A1 335/4885POLB 3957/4885KMT2A 2935/4885 |
| US-20040142948-A1 | Sulfonamides | UTS2R, PRSS2, STS | ALDH1A1 3733/4885POLB 4372/4885KMT2A 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.